Literature DB >> 32071907

Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition).

Shuqun Cheng1, Minshan Chen2, Jianqiang Cai3, Juxian Sun1, Rongping Guo2, Xinyu Bi3, Wan Yee Lau1,4, Mengchao Wu1.   

Abstract

Portal vein tumor thrombus (PVTT) is very common, and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the Consensus in 2016. Over the past several years, many new evidences for the treatment of PVTT become available especially for the advent of new targeted drugs which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer revised the 2016 version of consensus to adapt to the development of PVTT treatment. Future treatment strategies for HCC with PVTT in China would depend on new evidences from more future clinical trials.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Consensus; Hepatocellular carcinoma; Multidisciplinary therapy; Portal vein tumor thrombus

Year:  2019        PMID： 32071907      PMCID： PMC7024893          DOI： 10.1159/000503685

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


  32 in total

1.  Prediction of Early Treatment Response to Initial Conventional Transarterial Chemoembolization Therapy for Hepatocellular Carcinoma by Machine-Learning Model Based on Computed Tomography.

Authors:  Zhi Dong; Yingyu Lin; Fangzeng Lin; Xuyi Luo; Zhi Lin; Yinhong Zhang; Lujie Li; Zi-Ping Li; Shi-Ting Feng; Huasong Cai; Zhenpeng Peng
Journal:  J Hepatocell Carcinoma       Date:  2021-11-30

2.  Screening potential prognostic biomarkers for portal vein emboli in patients with hepatocellular carcinoma.

Authors:  Weijie Zhou; Da Lang Fang; Yongfei He
Journal:  J Gastrointest Oncol       Date:  2021-08

3.  Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.

Authors:  Xiao-Dong Zhu; Cheng Huang; Ying-Hao Shen; Yuan Ji; Ning-Ling Ge; Xu-Dong Qu; Lingli Chen; Wen-Kai Shi; Mei-Ling Li; Jin-Jin Zhu; Chang-Jun Tan; Zhao-You Tang; Jian Zhou; Jia Fan; Hui-Chuan Sun
Journal:  Liver Cancer       Date:  2021-03-30       Impact factor: 11.740

4.  Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study.

Authors:  Yanyan Cao; Tao Sun; Xiaopeng Guo; Tao Ouyang; Xuefeng Kan; Lei Chen; Bin Liang; Mingfu Wang; Chuansheng Zheng
Journal:  Front Oncol       Date:  2021-08-03       Impact factor: 6.244

Review 5.  Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.

Authors:  Yongkun Sun; Wen Zhang; Xinyu Bi; Zhengqiang Yang; Yu Tang; Liming Jiang; Feng Bi; Minshan Chen; Shuqun Cheng; Yihebali Chi; Yue Han; Jing Huang; Zhen Huang; Yuan Ji; Liqun Jia; Zhichao Jiang; Jing Jin; Zhengyu Jin; Xiao Li; Zhiyu Li; Jun Liang; Lianxin Liu; Yunpeng Liu; Yinying Lu; Shichun Lu; Qinghua Meng; Zuoxing Niu; Hongming Pan; Shukui Qin; Wang Qu; Guoliang Shao; Feng Shen; Tianqiang Song; Yan Song; Kaishan Tao; Aiping Tian; Jianhua Wang; Wenling Wang; Zhe Wang; Liqun Wu; Feng Xia; Baocai Xing; Jianming Xu; Huadan Xue; Dong Yan; Lin Yang; Jianming Ying; Jingping Yun; Zhaochong Zeng; Xuewen Zhang; Yanqiao Zhang; Yefan Zhang; Jianjun Zhao; Jianguo Zhou; Xu Zhu; Yinghua Zou; Jiahong Dong; Jia Fan; Wan Yee Lau; Yan Sun; Jinming Yu; Hong Zhao; Aiping Zhou; Jianqiang Cai
Journal:  Liver Cancer       Date:  2022-01-04       Impact factor: 12.430

6.  MRI-guided radiotherapy for PVTT in HCC patients: evaluation of the efficacy and safety.

Authors:  So Jung Lee; Myungsoo Kim; Yoo-Kang Kwak; Hye Jin Kang
Journal:  J Cancer Res Clin Oncol       Date:  2021-09-06       Impact factor: 4.322

7.  Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy.

Authors:  Wen-Yen Huang; Chiao-Ling Tsai; Jenny Y Que; Cheng-Hsiang Lo; Yu-Ju Lin; Yang-Hong Dai; Jen-Fu Yang; Po-Chien Shen; Mei-Hsuan Lee; Jason Chia-Hsien Cheng
Journal:  Liver Cancer       Date:  2020-03-10       Impact factor: 11.740

8.  Safety and efficacy of drug-eluting bead transarterial chemoembolization with CalliSpheres® microsphere for hepatocellular carcinoma with portal vein tumor thrombus: a preliminary study.

Authors:  Tan-Yang Zhou; Sheng-Qun Chen; Hong-Liang Wang; Sheng-Ming Weng; Guan-Hui Zhou; Yue-Lin Zhang; Chun-Hui Nie; Tong-Yin Zhu; Bao-Quan Wang; Zi-Niu Yu; Li Jing; Feng Chen; Jun-Hui Sun
Journal:  J Cancer       Date:  2021-06-01       Impact factor: 4.207

9.  A novel preoperative predictive model of 90-day mortality after liver resection for huge hepatocellular carcinoma.

Authors:  Yue Yin; Jian-Wen Cheng; Fei-Yu Chen; Xu-Xiao Chen; Xin Zhang; Ao Huang; De-Zhen Guo; Yu-Peng Wang; Ya Cao; Jia Fan; Jian Zhou; Xin-Rong Yang
Journal:  Ann Transl Med       Date:  2021-05

10.  Complete Response of Hepatocellular Carcinoma with Macroscopic Vascular Invasion and Pulmonary Metastasis to the Combination of Drug-Eluting Beads Transarterial Chemoembolization and Huaier Granule: A Case Report.

Authors:  Tan-Yang Zhou; Guo-Fang Tao; Sheng-Qun Chen; Hong-Liang Wang; Yue-Lin Zhang; Guan-Hui Zhou; Chun-Hui Nie; Tong-Yin Zhu; Bao-Quan Wang; Zi-Niu Yu; Li Jing; Feng Chen; Jun-Hui Sun
Journal:  Onco Targets Ther       Date:  2021-06-23       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.